Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q02161
UPID:
RHD_HUMAN
Alternative names:
RHXIII; Rh polypeptide 2; Rhesus D antigen
Alternative UPACC:
Q02161; Q02162; Q07618; Q16147; Q16235; Q16355; Q5VSK0; Q5XLS9; Q5XLT1; Q5XLT2; Q9NPK0; Q9UQ20; Q9UQ21; Q9UQ22; Q9UQ23
Background:
The Blood group Rh(D) polypeptide, also known as RHXIII, Rh polypeptide 2, or Rhesus D antigen, plays a crucial role in the erythrocyte membrane. It is believed to be part of an oligomeric complex, which likely facilitates transport or channel functions, essential for red blood cell integrity and function.
Therapeutic significance:
The Rh(D) polypeptide is pivotal in the development of Hemolytic disease of the fetus and newborn, RH-induced, a condition where maternal antibodies target fetal red cells. Understanding the role of Blood group Rh(D) polypeptide could open doors to potential therapeutic strategies, offering hope for preventing or treating this condition.